Home BreakingTelyRx Commences Trading on the OTCQX Market in the United States

TelyRx Commences Trading on the OTCQX Market in the United States

by Joseph Wilson
1 minutes read

Clearwater, Florida TelyRx Holdings Inc. (TSX: TELY) (OTCQX: TELYF) (“TelyRx” or the “Company”), a vertically integrated, technology-enabled healthcare and pharmacy services company, announced today that its subordinate voting shares have commenced trading on the OTCQX Best Market (“OTCQX”), the premier tier of the OTC Markets Group in the United States, under the symbol “TELYF”. TelyRx’s subordinate voting shares will also continue to trade on the TSX under the symbol “TELY”.

“Trading on the OTCQX provides U.S. investors with a straightforward way to access TelyRx’s shares on a recognized U.S. market and in U.S. dollars,” said Vanessa Slowey, President and Chief Executive Officer of TelyRx. “It also reinforces our commitment to the high standards our shareholders expect. As we continue to scale operations in response to growing customer demand, we believe improved market accessibility and liquidity are important foundations for long-term shareholder value.”

About TelyRx Holdings Inc.

TelyRx is a technology-enabled healthcare and pharmacy services company operating a digital pharmacy platform connecting patients with independent, state-licensed providers to access over 400 everyday medications across 48 U.S. states and territories. The company fulfills prescriptions through its licensed retail pharmacies and offers fast, convenient delivery of medications directly to patients’ doors.

About the OTCQX Best Market

The OTCQX Best Market is designed for established, investor-focused international and U.S. companies. To qualify for the OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. Investors can find real-time quotes and market information for the Company at www.otcmarkets.com.

For additional information, visit www.telyrx.com or contact:

Neil Weber Investor Relations (647) 222-0574 investors@telyrx.com

You may also like

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?